PWUP
ASPIRE BIOPHARMA HOLDINGS IN
ASPIRE BIOPHARMA HOLDINGS IN historical holders
total: 1
Oaktree Capital Management ASPIRE BIOPHARMA HOLDINGS IN transactions over time
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2022 Q2
- Held for:
- 4 quarters
- Latest activity:
- 2023 Q2
Howard Marks has been an institutional investor in ASPIRE BIOPHARMA HOLDINGS IN (PWUP) since 2022 Q2. According to 2026 Q2 report, Howard Marks doesn't hold any shares. The fund/company first acquired PWUP in 2022 Q2, initially purchasing 100,000 shares. Since the initial investment, Oaktree Capital Management has made 1 more transaction in this position.
When did Howard Marks exit their PWUP position?
Howard Marks no longer holds ASPIRE BIOPHARMA HOLDINGS IN (PWUP). They sold off their entire position in 2023 Q2, closing out an investment that began in 2022 Q2.
When did Howard Marks first invest in PWUP?
Howard Marks first invested in ASPIRE BIOPHARMA HOLDINGS IN (PWUP) in 2022 Q2 at the reported quarter-end price of $9.98 per share, acquiring 100,000 shares in their initial purchase.
What is Howard Marks's average cost basis for PWUP?
Based on historical transaction data, Howard Marks's estimated cost basis for ASPIRE BIOPHARMA HOLDINGS IN (PWUP) is approximately $9.98 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $9.98
- Weighted AVG sell price:
- $10.50
PWUP transactions history by Oaktree Capital Management
2 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q2
|
0.00%
|
0
|
$10.50
|
|
-100% (-100,000)
|
-0.01%
|
|
2022 Q2
|
0.01%
|
100,000
|
$9.98
|
$998,000
|
new
|
+0.01%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.